Skip to main content

Table 1 Patients’ baseline characteristics

From: Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Variable

Value (N = 198)

Age (y), mean ± SD

61.11 ± 11.36

Weight (kg), mean ± SD

66.93 ± 14.74

Height (cm), mean ± SD

166.44 ± 9.88

BSA (m2), mean ± SD

1.75 ± 0.21

Smokers, n (%)

132 (66.67)

Diagnosis, n (%)

 

 NSCLC

186 (93.94)

 MPM

12 (6.06)

Sex, n (%)

 

 Male

130 (65.66)

 Female

68 (34.34)

Stage 4, n (%)

 

 NSCLC

168 (90.32)

 MPM

2 (16.67)

Laboratory tests, mean ± SD

 

 SCr (mg/dL)

1.02 ± 0.22

 Bilirubin (mg/dL)

0.46 ± 0.30

 BUN (mg/dL)

31.24 ± 10.34

 AST (units/L)

23.78 ± 21.72

 ALT (units/L)

23.99 ± 17.83

 PLT (cells/μL)

324,653 ± 109,183

 WBC (cells/μL)

10,519 ± 4920

 Neutrophil (cells/μL)

7743 ± 4541

 Hb (g/dL)

12.68 ± 1.90

  1. SD standard deviation, BSA body surface area, NSCLC non-small cell lung cancer, MPM malignant pleural mesothelioma, SCr serum creatinine, AST aspartate aminotransferase, ALT alanine transaminase, PLT platelet, WBC white blood cell, BUN blood urea nitrogen, Hb hemoglobin